Skip to main content

Peripheral Neuropathy and cannabis in Mississippi

The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Not on the qualifying list
✗ No
LEGAL
Up to 3.5 g cannabis-eq…
POSSESSION
$25/yr
STATE FEE
3–14 d
TIMELINE
Not on the qualifying list. The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.

Mississippi statute and program

The Mississippi Medical Cannabis Program is the operating authority for Mississippi patient certification. The authoritative legal text is: Mississippi Medical Cannabis Act: Senate Bill 2095 of 2022 (codified at Miss. Code Ann. §41-137-1 et seq.). The program portal is at Mississippi Medical Cannabis Program.

What the evidence says about cannabis and Peripheral Neuropathy

Peripheral neuropathy is damage to or dysfunction of the peripheral nervous system (nerves outside the brain and spinal cord). Common causes include diabetes mellitus, chemotherapy, HIV infection, alcohol use, autoimmune disease, vitamin deficiency, infection, trauma, and inherited disorders. Symptoms typically include burning or shooting pain, tingling, numbness, weakness, and loss of coordination, most often in a stocking-glove distribution affecting feet first and then hands.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Peripheral Neuropathy page.

How to qualify in Mississippi

The Mississippi Medical Cannabis Program requires the following registration steps for a Peripheral Neuropathy patient (or any qualifying diagnosis):

  1. See a Mississippi-licensed practitioner registered with the MMCP. Under the Mississippi Medical Cannabis Act (SB 2095, 2022), a Mississippi-licensed physician, NP, PA, or optometrist who has completed the MSDH Medical Cannabis Program (MMCP) practitioner education course may certify a patient. Qualifying conditions under §41-137-3 include cancer, Parkinson’s, Huntington’s, MS, ALS, seizures, Crohn’s, ulcerative colitis, sickle-cell, Alzheimer’s, autism, cachexia, severe nausea, chronic and debilitating pain, PTSD, severe intractable pain, and opioid-use disorder.
  2. Apply through the Mississippi Medical Cannabis Program portal. The practitioner submits the written certification electronically. The patient then completes the online registration in the MMCP patient portal with a Mississippi driver license or state ID and a passport-style photo. Caregivers are registered through the same portal and pass a state and federal background check.
  3. Pay the $25 state registration fee. The annual Mississippi MMCP patient registry card fee is $25 (caregiver registration is also $25). Veterans, Medicaid patients, and patients with terminal illness pay a reduced fee of $15. Fees are paid online through the MMCP portal at registration.
  4. Receive the registry card and purchase from a Mississippi dispensary. Mississippi MMCP registry cards are typically issued within five business days of complete application. With the card, patients may purchase up to 3 Mississippi Medical Cannabis Equivalency Units per week from any of the licensed Mississippi dispensaries. Mississippi does not honor out-of-state medical cards. Cards renew annually with a fresh practitioner certification.
State registration fee
$25
Physician visit (typical)
$200–$350
Certification to card
3–14 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Mississippi registration steps, fees, and reciprocity rules, see the Mississippi cannabis-laws page.

ICD-10 code

A certifying physician documenting Peripheral Neuropathy for the Mississippi medical cannabis program will typically record ICD-10 G62.9 or SNOMED-CT 42658009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Mississippi list Peripheral Neuropathy as a qualifying condition for medical cannabis?

No. Mississippi's qualifying-condition list does not currently include Peripheral Neuropathy, and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Peripheral Neuropathy in Mississippi have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Mississippi program rules change, so verify the current list with the regulator before drawing a final conclusion.

How do I get a Mississippi medical marijuana card for Peripheral Neuropathy?

Because Mississippi does not currently list Peripheral Neuropathy as a qualifying condition, a card for Peripheral Neuropathy alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Mississippi who is registered with Mississippi Medical Cannabis Program and willing to evaluate Peripheral Neuropathy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Mississippi does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Mississippi Medical Cannabis Program site at https://mmcp.ms.gov/; the state updates fees, forms, and physician registration rules periodically.

What does the evidence say about cannabis for Peripheral Neuropathy?

For Peripheral Neuropathy, evidence is described as moderate (supportive controlled studies exist but the picture is mixed). The mmjnow condition page for Peripheral Neuropathy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Peripheral Neuropathy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Peripheral Neuropathy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Peripheral Neuropathy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Mississippi Medical Cannabis Act: Senate Bill 2095 of 2022 (codified at Miss. Code Ann. §41-137-1 et seq.)accessed May 16, 2026
  2. Mississippi State Department of Health: Medical Cannabis Programaccessed May 16, 2026
  3. Mississippi Department of Revenue: Cannabis Equivalency Unitaccessed May 16, 2026
  4. Wikipedia: Cannabis in Mississippiaccessed May 16, 2026
  5. Miss. Code Ann. §41-29-139: Prohibited acts; penalties (controlled substances)accessed May 18, 2026
  6. In re Initiative Measure No. 65 v. Watson, 333 So. 3d 558 (Miss. 2021)accessed May 18, 2026
  7. Mississippi Legislature bill trackeraccessed May 18, 2026
  8. NORML: Mississippi Laws & Penaltiesaccessed May 18, 2026
  9. Marijuana Policy Project: Mississippiaccessed May 18, 2026
  10. National Academies of Sciences, Engineering, and Medicine (2017): The Health Effects of Cannabis and Cannabinoidsaccessed May 18, 2026
  11. NIH NINDS: Peripheral Neuropathyaccessed May 16, 2026